Fortrea price target lowered to $7 from $8 at Mizuho

Mizuho lowered the firm’s price target on Fortrea (FTRE) to $7 from $8 and keeps a Neutral rating on the shares as part of a Q2 earnings preview. The firm believes earnings visibility is solid for the hospital group while cost trends remain challenging for managed care companies. Mizuho says its survey of 215 physicians is positive for hospitals, neutral for clinical labs, and neutral-to-negative for managed care.